158 related articles for article (PubMed ID: 38491717)
21. In vitro and in vivo metabolism of a gamma-secretase inhibitor BMS-299897 and generation of active metabolites in milligram quantities with a microbial bioreactor.
Zhang D; Hanson R; Roongta V; Dischino DD; Gao Q; Sloan CP; Polson C; Keavy D; Zheng M; Mitroka J; Yeola S
Curr Drug Metab; 2006 Dec; 7(8):883-96. PubMed ID: 17168689
[TBL] [Abstract][Full Text] [Related]
22. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia.
Cox CD; Breslin MJ; Whitman DB; Schreier JD; McGaughey GB; Bogusky MJ; Roecker AJ; Mercer SP; Bednar RA; Lemaire W; Bruno JG; Reiss DR; Harrell CM; Murphy KL; Garson SL; Doran SM; Prueksaritanont T; Anderson WB; Tang C; Roller S; Cabalu TD; Cui D; Hartman GD; Young SD; Koblan KS; Winrow CJ; Renger JJ; Coleman PJ
J Med Chem; 2010 Jul; 53(14):5320-32. PubMed ID: 20565075
[TBL] [Abstract][Full Text] [Related]
23. Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human.
Waters NJ; Smith SA; Olhava EJ; Duncan KW; Burton RD; O'Neill J; Rodrigue ME; Pollock RM; Moyer MP; Chesworth R
Cancer Chemother Pharmacol; 2016 Jan; 77(1):43-62. PubMed ID: 26645404
[TBL] [Abstract][Full Text] [Related]
24. [Preclinical and clinical efficacy of orexin receptor antagonist Lemborexant (Dayvigo
Koebisu M; Koyama N; Nishida M; Muramoto K
Nihon Yakurigaku Zasshi; 2021; 156(2):114-119. PubMed ID: 33642529
[TBL] [Abstract][Full Text] [Related]
25. Metabolism distribution and excretion of a matrix metalloproteinase-13 inhibitor, 4-[4-(4-fluorophenoxy)-benzenesulfonylamino]tetrahydropyran-4-carboxylic acid hydroxyamide (CP-544439), in rats and dogs: assessment of the metabolic profile of CP-544439 in plasma and urine of humans.
Dalvie D; Cosker T; Boyden T; Zhou S; Schroeder C; Potchoiba MJ
Drug Metab Dispos; 2008 Sep; 36(9):1869-83. PubMed ID: 18566038
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of NS-105, a novel cognition enhancer. 1st communication: absorption, metabolism and excretion in rats, dogs and monkeys after single administration of 14C-NS-105.
Mukai H; Sugimoto T; Ago M; Morino A
Arzneimittelforschung; 1999 Nov; 49(11):881-90. PubMed ID: 10604039
[TBL] [Abstract][Full Text] [Related]
27. New metabolic and pharmacokinetic characteristics of thiocolchicoside and its active metabolite in healthy humans.
Trellu M; Filali-Ansary A; Françon D; Adam R; Lluel P; Dubruc C; Thénot JP
Fundam Clin Pharmacol; 2004 Aug; 18(4):493-501. PubMed ID: 15312157
[TBL] [Abstract][Full Text] [Related]
28. Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro.
Gerisch M; Heinig R; Engelen A; Lang D; Kolkhof P; Radtke M; Platzek J; Lovis K; Rohde G; Schwarz T
Drug Metab Dispos; 2018 Nov; 46(11):1546-1555. PubMed ID: 30171161
[TBL] [Abstract][Full Text] [Related]
29. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological characterization of a novel potent, selective, and orally active orexin 2 receptor antagonist, SDM-878.
Maehara S; Yuge N; Higashi C; Ota T; Furukawa J; Takeuchi T
Neuropsychopharmacol Rep; 2020 Jun; 40(2):182-189. PubMed ID: 32337858
[TBL] [Abstract][Full Text] [Related]
31. Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist.
Berger B; Dingemanse J; Sabattini G; Delahaye S; Duthaler U; Muehlan C; Krähenbühl S
Clin Pharmacokinet; 2021 Oct; 60(10):1349-1360. PubMed ID: 34002356
[TBL] [Abstract][Full Text] [Related]
32. Absorption, Distribution, Metabolism, and Excretion of the Androgen Receptor Inhibitor Enzalutamide in Rats and Dogs.
Ohtsu Y; Gibbons JA; Suzuki K; Fitzsimmons ME; Nozawa K; Arai H
Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):611-626. PubMed ID: 27590197
[TBL] [Abstract][Full Text] [Related]
33. The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468.
Treiber A; de Kanter R; Roch C; Gatfield J; Boss C; von Raumer M; Schindelholz B; Muehlan C; van Gerven J; Jenck F
J Pharmacol Exp Ther; 2017 Sep; 362(3):489-503. PubMed ID: 28663311
[TBL] [Abstract][Full Text] [Related]
34. Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia.
Roecker AJ; Reger TS; Mattern MC; Mercer SP; Bergman JM; Schreier JD; Cube RV; Cox CD; Li D; Lemaire W; Bruno JG; Harrell CM; Garson SL; Gotter AL; Fox SV; Stevens J; Tannenbaum PL; Prueksaritanont T; Cabalu TD; Cui D; Stellabott J; Hartman GD; Young SD; Winrow CJ; Renger JJ; Coleman PJ
Bioorg Med Chem Lett; 2014 Oct; 24(20):4884-90. PubMed ID: 25248679
[TBL] [Abstract][Full Text] [Related]
35. Disposition and metabolism of ticagrelor, a novel P2Y12 receptor antagonist, in mice, rats, and marmosets.
Li Y; Landqvist C; Grimm SW
Drug Metab Dispos; 2011 Sep; 39(9):1555-67. PubMed ID: 21670219
[TBL] [Abstract][Full Text] [Related]
36. Disposition of [14C]velnacrine maleate in rats, dogs, and humans.
Turcan RG; Hillbeck D; Hartley TE; Gilbert PJ; Coe RA; Troke JA; Vose CW
Drug Metab Dispos; 1993; 21(6):1037-47. PubMed ID: 7905382
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic disposition of anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in rats and dogs.
Furuta S; Tamura M; Hirooka H; Mizuno Y; Miyoshi M; Furuta Y
Eur J Drug Metab Pharmacokinet; 2013 Jun; 38(2):87-96. PubMed ID: 23436178
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
[TBL] [Abstract][Full Text] [Related]
39. The disposition of radioactivity after administration of the anthelminthic methyl-14C-5-cyclopropylcarbonyl-2-benzimidazole carbamate (ciclobendazole) to rats and dogs.
Brodie RR; Mayo BC; Chasseaud LF; Hawkins DR
Arzneimittelforschung; 1977; 27(3):593-8. PubMed ID: 577426
[TBL] [Abstract][Full Text] [Related]
40. Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double-blind, placebo-controlled phase 2 study.
Uchiyama M; Kambe D; Imadera Y; Kajiyama Y; Ogo H; Uchimura N
Psychopharmacology (Berl); 2022 Jul; 239(7):2143-2154. PubMed ID: 35296912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
